NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN
AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S
REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY
OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE
UNLAWFUL  

Reference is made to Soft Softox Solutions AS' (the "Company") notice on 14
August 2025 regarding entering into a financing facility with the global
investment fund Long State Investments Limited ("Long State"). As commission for
the guarantee facility, Long State shall receive an implementation fee of up to
30 million shares in SoftOx. 

The board has today resolved to issue 15 million shares in SoftOx as the first
tranche of the 30 million share implementation fee, under the agreement.  The
subscription price was NOK 0,1004, equal to the VWAP of SoftOx's shares on 13
August 2025. The new share capital following completion of this issue will be
NOK 45 108 339,88 divided into 2 255 416 994 shares, each with a par value of
NOK 0,02.  

Deviation from shareholders' preferential rights 
The board of directors has considered the private placement in light of the
equal treatment principles under the Norwegian Securities Trading Act and Oslo
Børs' Oslo Rule Book II - Membership and Trading Rules and Oslo Børs' Circular
no. 2/2014, and is of the opinion that the waiver of the preferential rights
inherent in the following private placement is considered necessary in the
interest of time and successful completion in order to secure funding of SoftOx.
Taking into consideration the time, costs, and expected terms of alternative
methods of securing the necessary funding, the board of directors concluded that
the completion of the private placements, including the waiver of the
preferential rights inherent to the private placements, is in the common
interest of the shareholders of SoftOx. 

Further, the board assessed whether a subsequent offering should be carried out.
As the private placement is limited and considering the cost inherent in a
subsequent offering, the board concluded that a subsequent offering shall not be
carried out. 

For further information, please contact:  
Ulrik Spork, COB SoftOx Solutions AS, +45 31 38 83 87  
Ingrid Juven, CFO SoftOx Solutions AS, +47 918 76 165 
Mail: ir@soft-ox.com  

About SoftOx Solutions AS:  
SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company
listed on Euronext Growth Oslo. The company is developing highly effective
pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. The
technology is based on extensive research and development in partnership with
leading Nordic research institutes. 

About Long State